CellaVision and Sysmex Europe extend exclusive distribution agreement for the CellaVision® DM products

"CellaVision's cooperation with Sysmex Europe has developed successfully during the past years and has resulted in a steady market penetration and continuous sales growth. Sysmex is the leading company within laboratory diagnostics in Europe, and the fact that they will continue marketing and selling our systems to their clients gives us a very strong distribution channel as well as an excellent opportunity to penetrate the market further," says Yvonne Mårtensson, CEO of CellaVision.

 

The agreement comprises the majority of EMEA and implies that Sysmex Europe will continue selling, marketing, and supporting CellaVision's products with exclusive rights within agreed geographical areas until 2010.

 

Of CellaVision's total turnover in 2007 of SEK 74.6 million, the total of the EMEA area accounted for approximately 60 percent.

 

 

Yvonne Mårtensson, CEO, CellaVision AB
Tel: +46 46-286 44 00. E-mail: yvonne.martensson@cellavision.com

 

 

Sysmex Europe GmbH is a subsidiary of Sysmex Corporation, a leading international company designing and producing diagnostic solutions for medical laboratories worldwide. Located in Hamburg Sysmex Europe GmbH is taking care for bringing the latest healthcare relevant developments to the European, African, Middle Eastern, and Arabic markets through affiliate companies and local cooperation partners. Coordination of marketing and service activities and communication of regulatory and market demands to the Japanese mother company made Sysmex the market leader for haematology systems in Europe. The brand name Sysmex is well known and respected worldwide as being synonymous for innovation and reliability of products and services.

 

 

CellaVision AB develops, markets, and sells the market leading image analysis based systems for routine analysis of blood and other body fluids. The company has a core competence in development of software and hardware for automatic image analysis of cells and cell changes for applications in health and medical care. The company develops and markets systems for automatic differentials of white blood cells and red morphology, and software for education and quality assurance of differentials. The company's associates have expertise in advanced imaging analysis, artificial intelligence, and automated microscopy.

 

The company headquarters are in Lund, Sweden. The company also has subsidiaries in Florida, USA, Toronto, Canada and Yokohama, Japan. For more information, visit www.cellavision.com.

 

CellaVision's share is listed on First North at the OMX Stockholm Stock Exchange. The company's Certified Advisor is Remium AB.